Live Influenza Vaccine Provides Early Protection against Homologous and Heterologous Influenza and May Prevent Post-Influenza Pneumococcal Infections in Mice
Influenza and <i>S. pneumoniae</i> infections are a significant cause of morbidity and mortality worldwide. Intranasal live influenza vaccine (LAIV) may prevent influenza-related bacterial complications. The objectives of the study are to estimate resistance against early influenza infec...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2022-06-01
|
| Series: | Microorganisms |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2076-2607/10/6/1150 |
| _version_ | 1797484271395405824 |
|---|---|
| author | Yulia Desheva Galina Leontieva Tatiana Kramskaya Igor Losev Andrey Rekstin Nadezhda Petkova Polina Kudar Alexander Suvorov |
| author_facet | Yulia Desheva Galina Leontieva Tatiana Kramskaya Igor Losev Andrey Rekstin Nadezhda Petkova Polina Kudar Alexander Suvorov |
| author_sort | Yulia Desheva |
| collection | DOAJ |
| description | Influenza and <i>S. pneumoniae</i> infections are a significant cause of morbidity and mortality worldwide. Intranasal live influenza vaccine (LAIV) may prevent influenza-related bacterial complications. The objectives of the study are to estimate resistance against early influenza infection and post-influenza pneumococcal pneumonia after LAIV in mice. Mice were administered intranasally the monovalent LAIV A/17/Mallard Netherlands/00/95(H7N3), A/17/South Africa/2013/01(H1N1)pdm09 or trivalent LAIV 2017–2018 years of formulation containing A/17/New York/15/5364(H1N1)pdm09 vaccine strain. LAIV demonstrated early protection against homologous and heterologous infections with A/South Africa/3626/2013 (H1N1) pdm09 influenza virus on day six, following immunization. Following boost immunization, trivalent LAIV demonstrated a pronounced protective effect both in terms of lethality and pneumococcal lung infection when <i>S. pneumoniae</i> infection was performed three days after the onset of influenza infection. Conclusion: LAIV provides early protection against homologous and heterologous viral infections and has a protective effect against post-influenza pneumococcal infection. These data suggest that the intranasal administration of LAIV may be useful during the cycle of circulation not only of influenza viruses, but also of other causative agents of acute respiratory infections. |
| first_indexed | 2024-03-09T23:00:07Z |
| format | Article |
| id | doaj.art-7dd2720c11514e45b3d0ab39af8599f8 |
| institution | Directory Open Access Journal |
| issn | 2076-2607 |
| language | English |
| last_indexed | 2024-03-09T23:00:07Z |
| publishDate | 2022-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Microorganisms |
| spelling | doaj.art-7dd2720c11514e45b3d0ab39af8599f82023-11-23T18:03:49ZengMDPI AGMicroorganisms2076-26072022-06-01106115010.3390/microorganisms10061150Live Influenza Vaccine Provides Early Protection against Homologous and Heterologous Influenza and May Prevent Post-Influenza Pneumococcal Infections in MiceYulia Desheva0Galina Leontieva1Tatiana Kramskaya2Igor Losev3Andrey Rekstin4Nadezhda Petkova5Polina Kudar6Alexander Suvorov7Scientific and Educational Center “Molecular Bases of Interaction of Microorganisms and Human” of the World-Class Research Center “Center for Personalized Medicine”, Federal State Budgetary Scientific Institution “Institute of Experimental Medicine”, 12 Academician Pavlov Street, 197376 Saint Petersburg, RussiaScientific and Educational Center “Molecular Bases of Interaction of Microorganisms and Human” of the World-Class Research Center “Center for Personalized Medicine”, Federal State Budgetary Scientific Institution “Institute of Experimental Medicine”, 12 Academician Pavlov Street, 197376 Saint Petersburg, RussiaScientific and Educational Center “Molecular Bases of Interaction of Microorganisms and Human” of the World-Class Research Center “Center for Personalized Medicine”, Federal State Budgetary Scientific Institution “Institute of Experimental Medicine”, 12 Academician Pavlov Street, 197376 Saint Petersburg, RussiaScientific and Educational Center “Molecular Bases of Interaction of Microorganisms and Human” of the World-Class Research Center “Center for Personalized Medicine”, Federal State Budgetary Scientific Institution “Institute of Experimental Medicine”, 12 Academician Pavlov Street, 197376 Saint Petersburg, RussiaScientific and Educational Center “Molecular Bases of Interaction of Microorganisms and Human” of the World-Class Research Center “Center for Personalized Medicine”, Federal State Budgetary Scientific Institution “Institute of Experimental Medicine”, 12 Academician Pavlov Street, 197376 Saint Petersburg, RussiaScientific and Educational Center “Molecular Bases of Interaction of Microorganisms and Human” of the World-Class Research Center “Center for Personalized Medicine”, Federal State Budgetary Scientific Institution “Institute of Experimental Medicine”, 12 Academician Pavlov Street, 197376 Saint Petersburg, RussiaScientific and Educational Center “Molecular Bases of Interaction of Microorganisms and Human” of the World-Class Research Center “Center for Personalized Medicine”, Federal State Budgetary Scientific Institution “Institute of Experimental Medicine”, 12 Academician Pavlov Street, 197376 Saint Petersburg, RussiaScientific and Educational Center “Molecular Bases of Interaction of Microorganisms and Human” of the World-Class Research Center “Center for Personalized Medicine”, Federal State Budgetary Scientific Institution “Institute of Experimental Medicine”, 12 Academician Pavlov Street, 197376 Saint Petersburg, RussiaInfluenza and <i>S. pneumoniae</i> infections are a significant cause of morbidity and mortality worldwide. Intranasal live influenza vaccine (LAIV) may prevent influenza-related bacterial complications. The objectives of the study are to estimate resistance against early influenza infection and post-influenza pneumococcal pneumonia after LAIV in mice. Mice were administered intranasally the monovalent LAIV A/17/Mallard Netherlands/00/95(H7N3), A/17/South Africa/2013/01(H1N1)pdm09 or trivalent LAIV 2017–2018 years of formulation containing A/17/New York/15/5364(H1N1)pdm09 vaccine strain. LAIV demonstrated early protection against homologous and heterologous infections with A/South Africa/3626/2013 (H1N1) pdm09 influenza virus on day six, following immunization. Following boost immunization, trivalent LAIV demonstrated a pronounced protective effect both in terms of lethality and pneumococcal lung infection when <i>S. pneumoniae</i> infection was performed three days after the onset of influenza infection. Conclusion: LAIV provides early protection against homologous and heterologous viral infections and has a protective effect against post-influenza pneumococcal infection. These data suggest that the intranasal administration of LAIV may be useful during the cycle of circulation not only of influenza viruses, but also of other causative agents of acute respiratory infections.https://www.mdpi.com/2076-2607/10/6/1150live influenza vaccineearly cytokinesinfluenza infection<i>Streptococcus pneumoniae</i> |
| spellingShingle | Yulia Desheva Galina Leontieva Tatiana Kramskaya Igor Losev Andrey Rekstin Nadezhda Petkova Polina Kudar Alexander Suvorov Live Influenza Vaccine Provides Early Protection against Homologous and Heterologous Influenza and May Prevent Post-Influenza Pneumococcal Infections in Mice Microorganisms live influenza vaccine early cytokines influenza infection <i>Streptococcus pneumoniae</i> |
| title | Live Influenza Vaccine Provides Early Protection against Homologous and Heterologous Influenza and May Prevent Post-Influenza Pneumococcal Infections in Mice |
| title_full | Live Influenza Vaccine Provides Early Protection against Homologous and Heterologous Influenza and May Prevent Post-Influenza Pneumococcal Infections in Mice |
| title_fullStr | Live Influenza Vaccine Provides Early Protection against Homologous and Heterologous Influenza and May Prevent Post-Influenza Pneumococcal Infections in Mice |
| title_full_unstemmed | Live Influenza Vaccine Provides Early Protection against Homologous and Heterologous Influenza and May Prevent Post-Influenza Pneumococcal Infections in Mice |
| title_short | Live Influenza Vaccine Provides Early Protection against Homologous and Heterologous Influenza and May Prevent Post-Influenza Pneumococcal Infections in Mice |
| title_sort | live influenza vaccine provides early protection against homologous and heterologous influenza and may prevent post influenza pneumococcal infections in mice |
| topic | live influenza vaccine early cytokines influenza infection <i>Streptococcus pneumoniae</i> |
| url | https://www.mdpi.com/2076-2607/10/6/1150 |
| work_keys_str_mv | AT yuliadesheva liveinfluenzavaccineprovidesearlyprotectionagainsthomologousandheterologousinfluenzaandmaypreventpostinfluenzapneumococcalinfectionsinmice AT galinaleontieva liveinfluenzavaccineprovidesearlyprotectionagainsthomologousandheterologousinfluenzaandmaypreventpostinfluenzapneumococcalinfectionsinmice AT tatianakramskaya liveinfluenzavaccineprovidesearlyprotectionagainsthomologousandheterologousinfluenzaandmaypreventpostinfluenzapneumococcalinfectionsinmice AT igorlosev liveinfluenzavaccineprovidesearlyprotectionagainsthomologousandheterologousinfluenzaandmaypreventpostinfluenzapneumococcalinfectionsinmice AT andreyrekstin liveinfluenzavaccineprovidesearlyprotectionagainsthomologousandheterologousinfluenzaandmaypreventpostinfluenzapneumococcalinfectionsinmice AT nadezhdapetkova liveinfluenzavaccineprovidesearlyprotectionagainsthomologousandheterologousinfluenzaandmaypreventpostinfluenzapneumococcalinfectionsinmice AT polinakudar liveinfluenzavaccineprovidesearlyprotectionagainsthomologousandheterologousinfluenzaandmaypreventpostinfluenzapneumococcalinfectionsinmice AT alexandersuvorov liveinfluenzavaccineprovidesearlyprotectionagainsthomologousandheterologousinfluenzaandmaypreventpostinfluenzapneumococcalinfectionsinmice |